Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk

Follow-up Clinical Trial

— IATROPREV  

Official title:

Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05045235
• Other study ID #: PI2021_843_0158
• Status: Recruiting
• Start date: September 1, 2021
• Est. completion date: September 2025

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Frédéric BLOCH, MD
• Phone: 03 22 45 57 20
• Email: bloch.frederic[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The IATROPREV project is an organizational innovation experimentation project, carried out in Hauts-de-France by the University hospitals of Amiens and Lille, the ARS and the URPS Doctors and Pharmacists of Hauts-de-France and following to the social security financing law of 2018, allowing experimentation with new organizations in the health sector, according to article 51. The objectives of this course are to improve the relevance of prescription in elderly people with multiple drugs as well as, the coordination of care between the city and the hospital through the sharing of information and the establishment of multi-professional consultations between the various care actors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patient hospitalized in the geriatric medicine department

• Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization;

• Numerous therapeutic modifications (3 or more);

• Drug interaction or introction of a new drug with one or more drug interactions;

• Medicinal product with a narrow therapeutic marge drug requiring close monitoring.

Exclusion Criteria:

• patient non hospitalized in the geriatric medicine department

Related Conditions & MeSH terms

• Consultation
• Follow-up
• Iatrogenic Effect
• Prescription

Locations

Country	Name	City	State
France	Amiens University Hospital	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of side effect number in ederly with polymedicated drugs	Change of side effect number in ederly with polymedicated drugs	up to 4 years